Billiontoone, Inc. (NASDAQ:BLLN – Get Free Report) CTO David Tsao sold 20,000 shares of the company’s stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $98.77, for a total value of $1,975,400.00. Following the completion of the transaction, the chief technology officer directly owned 1,000 shares in the company, valued at $98,770. This represents a 95.24% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
David Tsao also recently made the following trade(s):
- On Tuesday, August 25th, David Tsao sold 10,000 shares of Billiontoone stock. The stock was sold at an average price of $100.00, for a total value of $1,000,000.00.
- On Monday, August 10th, David Tsao sold 10,000 shares of Billiontoone stock. The stock was sold at an average price of $92.86, for a total value of $928,600.00.
- On Monday, June 15th, David Tsao sold 20,000 shares of Billiontoone stock. The stock was sold at an average price of $102.27, for a total value of $2,045,400.00.
Billiontoone Trading Up 0.3%
Shares of NASDAQ BLLN opened at $98.77 on Friday. Billiontoone, Inc. has a 12 month low of $61.96 and a 12 month high of $150.44. The company has a market cap of $4.66 billion and a price-to-earnings ratio of 141.10. The company has a quick ratio of 11.31, a current ratio of 11.69 and a debt-to-equity ratio of 0.17. The business has a fifty day simple moving average of $111.64 and a 200-day simple moving average of $95.81.
Institutional Trading of Billiontoone
Hedge funds have recently made changes to their positions in the stock. Integrated Wealth Concepts LLC purchased a new position in Billiontoone during the second quarter valued at approximately $29,000. Rossby Financial LCC acquired a new stake in shares of Billiontoone during the 4th quarter valued at $25,000. MCF Advisors LLC grew its holdings in shares of Billiontoone by 330.8% during the 2nd quarter. MCF Advisors LLC now owns 448 shares of the company’s stock valued at $54,000 after acquiring an additional 344 shares in the last quarter. Wells Fargo & Company MN purchased a new position in shares of Billiontoone during the 4th quarter valued at $76,000. Finally, Smartleaf Asset Management LLC acquired a new position in shares of Billiontoone in the fourth quarter worth $80,000.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently issued reports on BLLN shares. JPMorgan Chase & Co. cut their price target on shares of Billiontoone from $145.00 to $130.00 and set an “overweight” rating on the stock in a report on Thursday, August 6th. BTIG Research decreased their price objective on shares of Billiontoone from $142.00 to $130.00 and set a “buy” rating for the company in a research note on Thursday, August 6th. Guggenheim initiated coverage on shares of Billiontoone in a research report on Monday, June 29th. They set a “buy” rating and a $125.00 price objective on the stock. Wall Street Zen downgraded shares of Billiontoone from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Finally, Weiss Ratings upgraded Billiontoone from a “sell (d)” rating to a “sell (d+)” rating in a report on Tuesday, June 23rd. Seven equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $125.88.
Read Our Latest Stock Analysis on BLLN
About Billiontoone
BillionToOne, Inc is a molecular diagnostics company that develops blood-based tests designed to provide genetic and health information from small amounts of biological material. The company’s technology uses its proprietary quantitative counting template approach to improve the accuracy and sensitivity of molecular testing.
The company’s primary offerings include UNITY, a portfolio of prenatal genetic tests. These services support screening for chromosomal conditions, single-gene disorders and carrier status, and are designed to help healthcare providers assess fetal and maternal genetic risks using a maternal blood sample.
Featured Articles
- Five stocks we like better than Billiontoone
- Block Makes a Federal Trust Bank Move That Could Reshape Its Fintech Model
- Kroger’s Textbook Entry for Buy-and-Hold Investors
- AST SpaceMobile Looks to Extend Its 30-Day FCC Satellite Testing Window
- Amgen Drops 10% on a Trial It Didn’t Even Run
Receive News & Ratings for Billiontoone Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Billiontoone and related companies with MarketBeat.com's FREE daily email newsletter.
